Answers are grounded in this paper and cite their sources.
First introduced by Breems et al. in 2008 [1Breems D.A. Van Putten W.L.J. De Greef G.E. et al.Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype.J Clin Oncol. 2008; 26: 4791-4797Crossref PubMed Scopus (469) Google Scholar], the monosomal karyotype (MK) describes a type of chromosomal aberration pattern characterized by the presence of at least 2 autosomal monosomies or 1 monosomy plus 1 structural aberration. As shown in this publication, MK is associated with a marked deterioration of prognosis in acute myelogenous leukemia (AML) patients. Subsequent publications [2Deeg H.J. Scott B.L. Fang M. et al.Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.Blood. 2012; 120: 1398-1408Crossref PubMed Scopus (130) Google Scholar, 3McQuilten Z.K. Sundararajan V. Andrianopoulos N. et al.Monosomal karyotype predicts inferior survival independently of a complex karyotype in patients with myelodysplastic syndromes.Cancer. 2015; 121: 2892-2899Crossref PubMed Scopus (20) Google Scholar] clearly confirmed this cytogenetic prognostic category, for AML as well as for myelodysplastic syndromes (MDS) [4Patnaik M.M. Hanson C.A. Hodnefield J.M. et al.Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype.Leukemia. 2011; 25: 266-270Crossref PubMed Scopus (82) Google Scholar]. Moreover, an integration of the MK category into existing prognostic classification systems, such as the revised International Prognostic Scoring System (IPSS-R) [5Greenberg P.L. Tuechler H. Schanz J. et al.Revised international prognostic scoring system for myelodysplastic syndromes.Blood. 2012; 120: 2454-2465Crossref PubMed Scopus (1987) Google Scholar], was proposed [6Yang Y.-T. Hou H.-A. Liu C.-Y. et al.IPSS-R in 555 Taiwanese patients with primary MDS: integration of monosomal karyotype can better risk-stratify the patients.Am J Hematol. 2014; 89: E142-E149Crossref PubMed Scopus (17) Google Scholar]. The article by Pasquini et al. [7Pasquini M.C. Zhang M-J. Medeiros B.C. et al.Hematopoietic cell transplantation outcomes in monosomal karyotype myeloid malignancies.Blood Biol Marrow Ttansplant. 2016; 2: 248-257Abstract Full Text Full Text PDF Scopus (27) Google Scholar] demonstrates the influence of MK on survival and treatment outcome in a large, well-defined cohort of patients with AML and MDS undergoing allogeneic cell transplantation. The authors precisely demonstrate that patients with myeloid malignancies presenting with MK show decreased transplantation success and an adverse prognosis. The article again confirms the negative impact of MK in this cohort of patients. However, the question still remains as to why MK is so strongly associated with a negative impact and how it can help to refine prognostic classification in patients with AML and MDS. From a clinical point of view, beyond question, MK detects a subgroup of patients with a very poor prognosis. It is an easy-to-use tool for clinical practice and helps to identify this subgroup very easily, even for those not experienced in cytogenetic findings, which are composed in a language often not easily interpreted without special training. MK is very well validated, and there are only few arguments against the use of MK as a strong prognostic marker in myeloid malignancies. As shown by Pasquini et al., MK is clearly associated with inferior survival, and this effect is not overcome by intensive regimens like allogeneic cell transplantation. Regarding MDS, several authors have described similar effects. In 2012 Deeg et al. [2Deeg H.J. Scott B.L. Fang M. et al.Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.Blood. 2012; 120: 1398-1408Crossref PubMed Scopus (130) Google Scholar] stated that MK increases the risk of relapse and mortality, even within the groups of the 5-arm IPSS-R classification system. Specific therapies like 5-azacytidine were also unable to overcome the negative effect of the MK, and it was shown that the integration of MK in the IPSS-R was also helpful to determine the response to 5-azacytidine in high-risk MDS patients [8Cluzeau T. Mounier N. Karsenti J.-M. et al.Monosomal karyotype improves IPSS-R stratification in MDS and AML patients treated with azacitidine.Am J Hematol. 2013; 88: 780-783Crossref PubMed Scopus (16) Google Scholar]. Finally, it was shown that MK is clearly associated with the deletion of TP53 [9Gaillard J.-B. Chiesa J. Reboul D. et al.Monosomal karyotype routinely defines a poor prognosis subgroup in acute myeloid leukemia and is frequently associated with TP53 deletion.Leuk Lymph. 2012; 53: 336-337Crossref PubMed Scopus (12) Google Scholar], which implies that MK mainly defines a surrogate marker for unfavorable genetic alterations associated with poor prognosis, clonal instability, and an impaired response to disease-altering therapies. This, indeed, leads to the question about the cytogenetic view on MK. One of the main problems to solve in this context is the interrelation of complex abnormalities (CK) and MK and the question of whether CK or MK, or both in combination, are suitable markers to identify the highest proportion of patients with the worst prognosis in both AML and MDS. In 2012 Haferlach et al. [10Haferlach C. Alpermann T. Schnittger S. et al.Prognostic value of monosomal karyotype in comparison to complex aberrant karyotype in acute myeloid leukemia: a study on 824 cases with aberrant karyotype.Blood. 2012; 119: 2122-2125Crossref PubMed Scopus (62) Google Scholar] analyzed this question by comparing the predictive power of CK and MK regarding prognosis in a series of 824 patients with AML. They concluded that CK, defined as a clone with at least 4 abnormalities in 1 cell, represented the best marker for the detection of the prognostically worst subgroup and that the exclusive use of MK posed the risk of missing a relevant subset of patients with an adverse prognosis. On the other hand, the exclusive use of CK also inherited that risk but in a much smaller number of cases. Thus, the authors recommended the combined use of CK and MK [10Haferlach C. Alpermann T. Schnittger S. et al.Prognostic value of monosomal karyotype in comparison to complex aberrant karyotype in acute myeloid leukemia: a study on 824 cases with aberrant karyotype.Blood. 2012; 119: 2122-2125Crossref PubMed Scopus (62) Google Scholar]. Regarding MDS, Valcarcel et al. [11Valcarcel D. Adema V. Solé F. et al.Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome.J Clin Oncol. 2013; 31: 916-922Crossref PubMed Scopus (61) Google Scholar] analyzed 1054 patients with primary MDS and came to the conclusion that MK is closely correlated with the number of abnormalities per clone and does not add any additional independent prognostic information. Another question is whether distinct abnormalities with a known adverse prognosis influence the predictive value of MK. A main suspect in this context is monosomy 7, one of the most frequent monosomies in AML and MDS and associated with a poor prognosis. Based on a study of 127 patients, Patnaik et al. [4Patnaik M.M. Hanson C.A. Hodnefield J.M. et al.Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype.Leukemia. 2011; 25: 266-270Crossref PubMed Scopus (82) Google Scholar] analyzed its influence in MDS and concluded that the effect of MK is independent of monosomy 7, whereas Valcarcel et al. [11Valcarcel D. Adema V. Solé F. et al.Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome.J Clin Oncol. 2013; 31: 916-922Crossref PubMed Scopus (61) Google Scholar] found no impact of MK independent from monosomy 5 and/or 7. Interestingly, Pasquini et al. [7Pasquini M.C. Zhang M-J. Medeiros B.C. et al.Hematopoietic cell transplantation outcomes in monosomal karyotype myeloid malignancies.Blood Biol Marrow Ttansplant. 2016; 2: 248-257Abstract Full Text Full Text PDF Scopus (27) Google Scholar] also found no correlation between monosomy 7 and the predictive power of MK, supporting the observations of Patnaik et al. However, the fact that monosomy 7 occurs in both highly complex and noncomplex karyotypes and that the number of abnormalities is a very strong prognostic factor could explain the different results in the studies. Possibly, −7 in a less complex karyotype (eg, with 1 additional abnormality, thus fulfilling the definition of MK) influences the prognosis much more because −7 is part of a very complex karyotype, accompanied by many other aberrations. Additionally, from the cytogenetic point of view, some monosomies exclusively occur as part of highly complex abnormal karyotypes and hence detect highly unstable clones with a high number of chromosomal alterations, which are, in addition, often linked to TP53 deletions and/or mutations. This was repeatedly shown for monosomy 5, which does not occur as a single anomaly and is, instead, a “pseudo-monosomy” arising from multiple chromosomal rearrangements [12Galván A.B. Mallo M. Arenillas L. et al.Does monosomy 5 really exist in myelodysplastic syndromes and acute myeloid leukemia?.Leuk Res. 2010; 34: 1242-1245Abstract Full Text Full Text PDF PubMed Scopus (20) Google Scholar]. Thus, taking these facts together, the cytogenetic point of view recognizes the risk of an oversimplification by using categories like MK that block our view to the biological background of the origin of complex, instable clones and its adverse prognosis. However, as shown by Pasquini et al. [7Pasquini M.C. Zhang M-J. Medeiros B.C. et al.Hematopoietic cell transplantation outcomes in monosomal karyotype myeloid malignancies.Blood Biol Marrow Ttansplant. 2016; 2: 248-257Abstract Full Text Full Text PDF Scopus (27) Google Scholar], MK is a valuable and easy-to-use tool to identify the subgroup of patients with the highest risk and, hence, is desirable from the clinical point of view.
No takes yet. Share an insight, caveat, or question.
Julie Schanz (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: